NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/06/2026
Voltar para busca
Dado oficial do USPTO
T G TRAFFIKGENE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
23/06/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42, 44
Data de depósito
22/07/2024
Data de registro
23/06/2026
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/06/2026
Última transação
23/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
3
Tipo de titular
99
Localização do titular
Santiago de Compostela, ES
Examinador
KOPENSKI, CLAUDIA ANN
Unidade examinadora
O20
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of a green stylized double helix design with a stylized green letter "T" on the left of the helix and stylized green "G" on the right of the helix. Below is the word "TRAFFIKGENE" in green stylized font.
Titulares e representantes
Titulares
U. C. (pessoa física)
Representantes
Ricardo Fischer ArentFox Schiff LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biologyother than for medical or veterinary use; Nucleic acidsother than for medical or veterinary purposes; Nucleic recombinant acidsother than for medical or veterinary purposes; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processesother than for medical use; Biological tissue culturesother than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing other than for medical or veterinary purposes; Biological preparationsother than for medical or veterinary purposesbiological preparations for use in industry and sciencethe agriculture and the food industry; Aldehydes; Active chemical ingredients for use in the manufacture of pharmaceuticalstransfection reagents for use in the manufacture of pharmaceuticalsin protein productionthe manufacture of biologicsviral vectors and vaccine productionthe engineering of producer and stable cell lines for drug discovery and preclinical developmentlaboratory kits for use in transfection procedures for use in the manufacture of pharmaceuticalsin protein productionthe manufacture of biologicsviral vectors and vaccine productionthe engineering of producer and stable cell lines for drug discovery and preclinical development which are comprised of a peptide-based transfection reagentnucleic acidsproteinssmall molecules being organic compoundsa combination of these elements for enhancing membrane permeation for the introduction of relevant biological moleculesgene materialproteinspeptidesantibodies inside cultured cells; Salts being chemical preparations in the nature of salts for industrialpharmaceutical and agricultural purposes
Classe 5
Pharmaceuticals in the nature of advanced therapeutic medicinal productsnamely RNA therapiesgene and cell therapiesas well as enzyme replacement therapiesimmunotherapiesvaccines all for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; medical preparations in the nature of medical preparations for gene therapyimmunotherapyenzyme replacement and vaccinations all for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; veterinary preparations for gene therapy for pets and farm animalsall for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes being advanced therapeutic medicinal products in the nature of RNA therapy preparationsmRNAsiRNAantisense oligonucleotide therapies for the treatment of cancergenetic disordersinfectious diseasesimmune-mediated diseasesgene therapy preparations for the treatment of inherited genetic disorderscancerrare diseasesenzyme replacement therapies for the treatment of metabolic and lysosomal storage disordersvaccines for prophylactic and therapeutic useimmunotherapies for the treatment of cancerautoimmune diseasesinflammatory diseasescell therapies for the treatment of cancergenetic disordersdegenerative diseases; Medicines for human purposes being RNA therapiesgene and cell therapiesas well as enzyme replacement therapiesimmunotherapiesvaccines all for the treatment of oncological disorders particularly melanoma or lung cancermetabolic diseases particularly lysosomal storage diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Biological preparations for medical purposes for the treatment of rare diseasesgenetic diseasescancer or the prophylaxis of viral diseases; Pharmaceutical preparationsadvanced therapeutic medicinal products being pharmaceuticals for enzyme replacement therapiesimmunotherapiesvaccines for the treatment of oncological disorders particularly melanoma or lung cancermetabolic diseases particularly lysosomal storage diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nutraceutical preparations for therapeutic and medical purposes for the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemical preparations for pharmaceutical purposesfor the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemical preparations for medical purposesnamely for the treatment of rare diseasesgenetic diseasescancer and the prophylaxis of viral diseases; Chemico-pharmaceutical preparations in the nature of formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposesnamely formulations comprising at least a mixture of one or more peptide or peptide amphiphile molecules and one or more nucleic acids and proteins for the treatment of oncological disordersmetabolic diseasesautoimmune diseasesinfectious diseasesother rare genetic diseases produced by mutations causing a missing gene or the expression of a faulty one; Nucleic acids for medical or veterinary purposes; Nucleic recombinant acids for medical or veterinary purposes
Classe 42
Scientific and technological servicesscientific researchanalysistestingmodelingchemical designsynthesis and characterization as well as related research and design services in the field of bioinformatics and structure-activity relationship researchparticularly that driven by machine learning and related algorithms; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for others for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services in the nature of research and development services in the field of peptide chemistryorganic chemistrysupramolecular chemistry and biological chemistry
Classe 44
Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
23/06/2026
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2026
PUBO
PUBLISHED FOR OPPOSITION
05/05/2026
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
29/04/2026
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/04/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/03/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/03/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
23/03/2026
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
19/02/2026
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
19/02/2026
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
19/02/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/01/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/01/2026
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
13/01/2026
RDX3
NOTIFICATION FOR REQ FOR RECON DENIED NO APPEAL FILED
06/01/2026
RDX1
ACTION FOR REQ FOR RECON DENIED NO APPEAL FILED E-MAILED
06/01/2026
RRDX
ACTION REQ FOR RECON DENIED NO APPEAL FILED COUNTED NOT MAILED
06/01/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
18/12/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
18/12/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
18/12/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
14/10/2025
GNFR
FINAL REFUSAL E-MAILED
14/10/2025
CNFR
FINAL REFUSAL WRITTEN
14/10/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/09/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/09/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/09/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
29/07/2025
GNRT
NON-FINAL ACTION E-MAILED
29/07/2025
CNRT
NON-FINAL ACTION WRITTEN
29/07/2025
DOCK
ASSIGNED TO EXAMINER
08/07/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/04/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/04/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/04/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/02/2025
GNRT
NON-FINAL ACTION E-MAILED
11/02/2025
CNRT
NON-FINAL ACTION WRITTEN
11/02/2025
DOCK
ASSIGNED TO EXAMINER
11/02/2025
MDSM
NOTICE OF DESIGN SEARCH CODE E-MAILED
10/02/2025
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
10/02/2025
NWAP
NEW APPLICATION ENTERED
22/07/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace T G TRAFFIKGENE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.